Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002514608 | SCV003236108 | pathogenic | Li-Fraumeni syndrome | 2022-09-21 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This variant disrupts a region of the TP53 protein in which other variant(s) (p.Pro152Arg) have been determined to be pathogenic (PMID: 12826609, 29979965, 30224644; Invitae). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. ClinVar contains an entry for this variant (Variation ID: 133282). This variant has not been reported in the literature in individuals affected with TP53-related conditions. This variant is not present in population databases (gnomAD no frequency). This variant, c.448_459del, results in the deletion of 4 amino acid(s) of the TP53 protein (p.Thr150_Pro153del), but otherwise preserves the integrity of the reading frame. |
Myriad Genetics, |
RCV004019663 | SCV004931432 | likely pathogenic | Li-Fraumeni syndrome 1 | 2024-02-14 | criteria provided, single submitter | clinical testing | This variant is considered likely pathogenic. Functional studies indicate this variant impacts protein function [PMID: 29979965]. This variant is expected to disrupt protein structure [Myriad internal data]. |
Laboratory of Translational Genomics, |
RCV000119795 | SCV000154267 | not provided | Sarcoma | no assertion provided | not provided |